RG7716 improves visual acuity in subjects with Diabetic Macular Edema in a Phase 2 study

(c)Pharmacodia.com

Genentech announced results from the Phase II BOULEVARD study, which is evaluating subjects with vision loss from diabetic macular edema (DME), where treatment with intravitreal RG7716 was observed to be clinically meaningful and statistically significant in improvement of visual acuity gains compared with ranibizumab alone.